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Background. Psoriasis is a common inflammatory and immune-mediated skin disease. There is growing controversy as to whether
cardiovascular risk is elevated in psoriasis. A number of studies suggest a high prevalence of cardiovascular risk factors as well
as cardiovascular diseases in psoriasis patients. Objective. The objective of this study was to estimate cardiovascular risk score in
psoriasis patients and the relation between cardiovascular risk and psoriasis features. Cardiovascular risk was assessed by CUORE
project risk score built within the longitudinal study of the Italian CUORE project and suited to populations with a low rate of
coronary heart disease. Results. A case-control study in 210 psoriasis outpatients and 111 controls with skin diseases other than
psoriasis was performed. CUORE project risk score was higher in patients than controls (6.80± 6.34 versus 4.48± 4.38, 𝑃 < 0.001).
Compared to controls, psoriasis patients have higher risk of developing major cardiovascular events. Cardiovascular risk was not
related to psoriasis characteristics.Conclusion. Increased focus on identifying cardiovascular risk factors and initiation of preventive
lifestyle changes or therapeutic interventions in patients with psoriasis is warranted.
1. Introduction
Psoriasis is a common inflammatory, immune-mediated skin
disease [1]. It affects approximately 2-3% of the Western
population, with varying prevalence among different ethnic
groups and a similar prevalence in men and women [2].
Although psoriasis can present at any age, it has two peak
periods of onset: at 15 to 25 years of age (type I psoriasis) and
at 40 to 60 years of age (type II psoriasis) [3].
In addition to its cutaneous manifestations, psoriasis
has been associated with inflammatory arthritis, depression,
anger, anxiety, frustration, and considerable health-related
quality of life impairment, which appear independent of
objective disease severity [4, 5].
Once symptoms occur, the disease is characterized by
a chronic course; spontaneous, long-term remissions occur
in a minority of patients. Clinical manifestations are het-
erogeneous, ranging from limited to very extensive disease
[1]. Approximately 80% to 85% of patients have limited skin
involvement, whereas 15% to 20% have more extensive skin
involvement that may require systemic therapy [6].
The exact etiology of psoriasis is not entirely elucidated;
there is strong evidence that the interaction of multiple
genetic, immunologic, and environmental factors contribute
to its pathogenesis. As the understanding of psoriasis has
evolved, so has the perception of disease pathophysiology
[1, 7], characterized by increased T lymphocyte activity
[6]. T-helper (Th)-1, Th-17, and Th-22 cell populations are
expanded and stimulated to release inflammatory cytokines
(i.e., tumour necrosis factor-𝛼 (TNF-𝛼), interleukin- (IL-)
17, and IL-22) demonstrating the extent of systemic involve-
ment. Accordingly, the inflammation that drives psoriatic
pathology is systemic [1]; this concept carries important
public-health implications and has prompted a growing
body of research. As a systemic inflammatory condition,
psoriasis may be analogous to other inflammatory, immune
disorders, such as systemic lupus erythematosus and rheuma-
toid arthritis. Since the risk of myocardial infarction and
other cardiovascular diseases is firmly established in these
specific disorders, attention has been focused on whether
cardiovascular risk factors and cardiovascular diseases are
increased in patients with psoriasis [4, 8].
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Although, the initial link between psoriasis and coronary
artery disease was suggested in the 1970s [9, 10], there is
growing controversy as to whether cardiovascular risk is
elevated in psoriasis. A number of studies suggest a high
prevalence of cardiovascular risk factors (e.g., smoking,
diabetes mellitus, hypertension, and hyperlipidemia) as well
as cardiovascular disease (CVD) in psoriasis patients [6]. A
major limitation of most of these studies is that they focus on
highly selected psoriasis patients, such as those hospitalized
for their disease and are therefore likely biased toward patient
populations withmore severe disease.This selection biasmay
be important since some studies indicate that the increased
cardiovascular risk may be confined to patients with severe
skin disease [6].
Current recommendations on the prevention of coronary
heart disease in clinical practice stress the need to base
intervention on an assessment of the individual’s total burden
of risk rather than on the level of any particular risk factor.
This is because most people who develop atherosclerotic
cardiovascular disease have several risk factors which interact
to produce their total risk. It follows that there is a need for
clinicians to be able to estimate total risk of cardiovascular
disease [11].
In contrast to the general population and patients with
diabetes, rheumatoid arthritis, and systemic lupus erythe-
matosus, there are very few information about the estimation
of cardiovascular risk by means of specific risk scores in pso-
riasis patients using predictive equations [12]. Recent studies
have examined the risk of cardiovascular events in patients
with psoriasis according to the Framingham cardiovascular
risk prediction score and documented that a high proportion
of patients with psoriasis were at substantially increased risk
and making them potential candidates for pharmacological
cardiovascular primary prophylaxis [8]. The Framingham
risk score is a tool to predict the absolute risk of major
coronary and cerebrovascular events at 5 and 10 years in
adults from 30 to 74 years of age by stratifying patients into 3
risk categories: patients scoring less than 10% are at low risk,
those between 10% and 20% have a moderate risk, and those
scoring 20% ormore are at high risk.This score is appropriate
for United States, Australia, and New Zealand populations
[11].
Until the recent publication of the Italian risk charts of
the “CUORE project,” the Framingham risk function was
applied for the Italian population. However, it is known that
the Framingham function-based risk charts generally tend
to overestimate absolute risk in populations with a low rate
of coronary heart disease, such as Italy and, sometimes, this
overestimation may occur in countries with a high rate [13].
Moreover, recent studies applying Framingham risk function
to data from Danish and German prospective studies have
demonstrated that the Framingham risk function clearly
overestimates coronary heart disease risk also in these pop-
ulations [11].
The objective of the current study was to estimate car-
diovascular risk score in psoriasis patients and the relation
between cardiovascular risk and psoriasis features in a real-
world setting.
2. Materials and Methods
An observational case-control study was performed at the
psoriasis outpatient clinic of Dermatology Department (Uni-
versity of Palermo, Italy), over a period of 1 year from
January 2012 through December 2012. The control group
was recruited from nonpsoriatic patients attending the
same Dermatology Department and included patients with
melanocytic naevi, cutaneousmelanoma, nonmelanoma skin
cancer, cutaneous infectious diseases, and other benign con-
ditions. Patients suffering from inflammatory skin conditions
or autoimmune diseases were excluded from the control
group. Informed consent was obtained from all patients
prior to inclusion and confidentiality of personal data was
warranted.
The 10-year cardiovascular risk was assessed using the
CUORE project risk score built within the Italian CUORE
project. The CUORE project—epidemiology and prevention
of ischaemic heart diseases—launched in 1998, is financed
by 1% of the National health fund and is coordinated by the
Istituto Superiore di Sanita`. It is a prospective fixed-cohort
study, including cohorts from the north, the centre, and the
south of Italy. Since 2005, the project is listed among those
of the National Centre for Disease Prevention and Control,
Ministry of Health, Rome.
TheCUOREproject risk score allows estimating the prob-
ability of experiencing a first cardiovascular event (myocar-
dial infarction, stroke) over the next 10 years knowing the
level of eight risk factors for cardiovascular disease: age,
gender, systolic blood pressure (SBP), total blood choles-
terol (TC), high-density lipoprotein-cholesterol (HDL-C),
diabetes mellitus, smoking habit, and use of antihypertensive
medication. It is validated in patients 35 to 69 years of
age and without previous major cardiovascular accidents.
Mathematical functions, derived from longitudinal studies
carried out on population groups followed up over time, are
used to assess the risk score. On the basis of the CUORE
project risk score, patients are classified as low risk (CUORE
project risk score < 3.0%), risk to be kept under control
through the adoption of a healthy lifestyle (CUORE project
risk score 3.0–19.9%), and high risk (CUORE project risk
score ≥ 20.0%).
Data were collected using the software cuore.exe, down-
loadable free of charge from the website of the CUORE
project http://www.cuore.iss.it/. Information recorded were
cigarette smoking, personal history of myocardial infarction,
stroke, hospitalization for major cardiovascular events and
medication use, and clinical type and duration of psoriasis.
Risk factors were assessed by using standardized proce-
dures. Laboratory analyses considered for risk assessment
were TC, HDL-C, and glycaemia. Participants were defined
as having diabetes mellitus when they were taking hypogly-
caemic medications (oral hypoglycaemic drugs or insulin),
had a fasting plasma glucose concentration ≥ 126mg/dL, or
had a personal clinical history of diabetes.
Patients and controls blood pressure was assessed by
trained technicians before their routine dermatologic fol-
lowup at the Dermatology Department of University of
Palermo. Blood pressure was measured twice on the right
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arm, using a mercury sphygmomanometer, with the partic-
ipant sitting after resting for 5 minutes. Systolic and dias-
tolic blood pressure was recorded (first and fifth Korotkoff
sounds); the average of twomeasurements, taken 5min apart,
was used as the study variable.
Inclusion criteria for psoriasis patients were a diagnosis
of psoriasis lasting at least 1 year; absence of any clinical
sign and symptom of articular involvement or diagnosis of
arthropathy; absence of any systemic treatment for psoriasis
in the previous 3 months prior to clinical evaluation. The
severity of the psoriasis was measured by means of the
PsoriasisArea and Severity Index (PASI), themost commonly
used tool to assess disease severity in patients with psoriasis
in clinical trials. It measures erythema, infiltration, scaling,
and extent of involvement of the four body areas (head, trunk,
arms, and legs). The PASI scale ranges from 0 to 72. Psoriasis
is classified as mild if the PASI is below 10 and moderate to
severe if it is 10 or above [14, 15]. Patients were considered to
have early-onset psoriasis if the onset age was <40 years.
Data management and statistical analysis were carried
out using WINKS SDA, version 7.0. Qualitative variables
were described as absolute and relative frequencies while
quantitative variables were described usingmeans ± standard
deviation (SD). P values < 0.05 were accepted as statistically
significant. The analysis was performed for the sample as a
whole and for subgroups of patients classified according to
disease severity (mild or moderate to severe) and type (type I
or type II psoriasis).
3. Results
The study included 210 patients and 111 controls. Mean age of
patients with psoriasis was 52.22 ± 9.85 years (mean ± SD)
and 142 (67.62%) were male. Disease severity was assessed
according to the psoriasis area and severity index. Seventy
(33.3%) patients had mild disease and 59.05% (124) had type
I psoriasis. The mean PASI was 15.44 ± 8.67 (range 4–46.7).
Psoriasis duration was 1 to 54 years (mean 14.18 ± 10.93).
The mean age of the nonpsoriatic group was 52.30 ± 9.55
years and 75 (67.57%) were male. Mean age (𝑃 = 0.994)
was similar in cases and controls. There were no significant
differences in gender between the groups (𝑃 = 0.992).
Seventy (63.06%) controls had nonmelanoma skin cancer,
melanocytic nevi, or cutaneous melanoma and 36.94% (41
controls) had cutaneous infectious diseases, such as der-
matophytosis, onychomycosis, candidiasis, pityriasis versi-
color, warts, condylomata, exanthematous viral diseases,
or leishmaniasis. Descriptive analyses of the demographic
characteristics of patients and controls appear in Table 1.
CUORE project risk score was calculated in patients and
controls and it was higher in patients than controls (mean
± SD, 6.80 ± 6.34 versus 4.48 ± 4.38, 𝑃 < 0.001). On the
basis of the CUORE project risk score, 87 (41.43%) psoriasis
patients had a low risk of suffering a major cardiovascular
event in ten next years, 112 (53.33%) an intermediate risk, and
11 (5.24%) a high risk, compared with 46.85% (52) (low risk)
and 53.15% (59) of subjects (intermediate risk) in the control
group (Table 2). In the low risk group, CUORE project risk
score mean was higher in patients than controls (1.81 ± 0.74
versus 1.28 ± 0.6, 𝑃 < 0.001). Mean age of patients (45.02 ±
6.79) and controls (45.56 ± 7.43) with a low risk score was
similar (𝑃 = 0.662). Evenly, in the intermediate risk group,
patients had a higher CUORE project risk score mean than
controls (8.9 ± 4.25 versus 7.30 ± 4.43, 𝑃 = 0.002). Mean age
of patients (56.6 ± 8.44) and controls (58.25 ± 6.98) with an
intermediate risk score was not significantly different (𝑃 =
0.063). We did not observe controls with a high risk score.
Patients with type II psoriasis had a higher CUORE
project risk score, but it could be because of a higher mean
age (𝑃 < 0.001). Indeed, CUORE project risk score mean
was no not significantly different in all age groups in type I
and II psoriasis (Table 3). There was no correlation between
psoriasis severity and CUORE project risk score (Table 4).
4. Discussion
Psoriasis has been associated with an increased risk of
metabolic syndrome and its components (diabetes mellitus,
hypertension, hyperlipidemia, obesity, and smoking). Diag-
nosis of metabolic syndrome carries with it an increased risk
of cardiovascular morbidity andmortality and has important
public-health implications [16].
The majority of epidemiological studies examining the
cardiovascular risk in psoriasis relied on Framingham risk
score [19–22] and one assessed DORICA, SCORE, and
REDIGOR risk score [12]. Framingham risk score is con-
sidered to overestimate cardiovascular risk in European
countries with a lower incidence of cardiovascular events
while DORICA, SCORE, and REDIGOR are more suited to
Mediterranean populations [12].
In our series, the 10-year CUORE project cardiovascular
risk score was assessed to patients and controls. Consistent
with previous research, this study found a greater cardiovas-
cular risk score in psoriasis patients than controls. However,
we report a higher proportion of patients with moderate car-
diovascular risk (53.33%) while aminority of patients (5.24%)
were at high risk of cardiovascular disease. We posit that this
was due to the overestimation of Framingham cardiovascular
risk score in European populations. According to previous
research,we found that cardiovascular risk increaseswith age.
There is growing controversy as to whether cardiovascu-
lar risk is elevated in patients with moderate to severe psori-
asis or those who had an earlier age of disease onset. Some
published studies indicate that the increased cardiovascular
risk may be confined to patients with severe skin disease [17].
However, studies that focused on patients hospitalized for
psoriasis may not be generalizable to the broader population
of patients with psoriasis because only a few patients with
the most severe disease require hospitalization. Furthermore,
patients hospitalized for any condition generally have higher
rates of comorbidities, smoking, and alcohol use, which can
increase the risk of death compared with individuals who are
not hospitalized [18].
In our series, consisted of 210 psoriasis outpatients, which
reflect the complete disease spectrum, course, and severity,
no relationship was found between disease severity and
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Table 1: Descriptive analysis of the demographic and clinical data of cases and controls.
Characteristics Psoriasis patients (𝑛 = 210) Controls (𝑛 = 111) 𝑃 value
Age (years), mean ± SD 52.22 ± 9.85 52.30 ± 9.55 𝑃 = 0.994
Gender
Male, % (𝑛) 67.62% (142) 67.57% (75) 𝑃 = 0.992
PASI, mean 15.44 ± 8.67
Range 4–46.7
PASI < 10, % (𝑛) 33% (70)
PASI ≥ 10, % (𝑛) 77% (140)
Psoriasis type I, % (𝑛) 59.05% (124)
Psoriasis type II, % (𝑛) 40.95% (86)
CUORE project risk score,
Mean ± SD 6.80 ± 6.34 4.48 ± 4.38 𝑃 < 0.001
35–44 years 2.32 ± 1.65 1.11 ± 0.74 𝑃 < 0.001
45–54 years 4.43 ± 3.47 2.53 ± 1.39 𝑃 < 0.001
55–69 years 12.99 ± 15.16 8.07 ± 4.68 𝑃 = 0.006
Table 2: Comparison of CUORE project risk score in patients and controls.
Cases (𝑛 = 210) Controls (𝑛 = 111) 𝑃 value
Low risk
% (𝑛) 41.43% (87) 46.85% (52) 𝑃 = 0.351
Age (years), mean ± SD 45.02 ± 6.79 45.56 ± 7.34 𝑃 = 0.662
Gender
Male, % (𝑛) 22.86% (48) 25.2% (28) 𝑃 = 0.635
Female, % (𝑛) 18.6% (39) 21.6% (24) 𝑃 = 0.405
CUORE project risk score,
Mean ± SD 1.81 ± 0.74 1.28 ± 0.69 𝑃 < 0.001
Intermediate risk
% (𝑛) 53.33% (112) 53.15% (59) 𝑃 = 0.975
Age (years), mean ± SD 56.6 ± 8.44 58.25 ± 6.98 𝑃 = 0.063
Gender
Male, % (𝑛) 40% (84) 42.4% (47) 𝑃 = 0.684
Female, % (𝑛) 13.3% (28) 10.8% (12) 𝑃 = 0.515
CUORE project risk score,
Mean ± SD 8.90 ± 4.25 7.30 ± 4.43 𝑃 = 0.002
High risk
% (𝑛) 5.24 (11) 0
Age (years), mean ± SD 64.73 ± 3.86
Gender
Male, % (𝑛) 4.77% (10)
Female, % (𝑛) 0.47% (1)
CUORE project risk score,
Mean ± SD 24.82 ± 3.19
cardiovascular risk score. Moreover, there was no correlation
between psoriasis type and cardiovascular risk; this relation
was not evaluated in previous studies. In a previous study,
no correlation between disease duration and Framingham
risk score has been reported [19]. Our findings, although
the number of psoriasis patients and controls are limited,
demonstrate that cardiovascular risk is higher in psoriasis
even when assessed by a risk score not previously used
in psoriasis patients and more suited to Mediterranean
populations.
The aim of cardiovascular disease risk charts is to be a
simple diagnostic and easily usable support in the clinical
practice of general practitioners and specialists.Theydescribe
the disease risk in a population much better than using any
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Table 3: Comparison of psoriasis type and cardiovascular risk.
Psoriasis type I (𝑛 = 124) Psoriasis type II (𝑛 = 86) 𝑃 value
Age (years), mean ± SD 48.5 ± 9.22 57.6 ± 8.23 𝑃 < 0.001
Gender
Male, % (𝑛) 72.6% (90) 60.5% (52)
𝑃 = 0.065
Female, % (𝑛) 27.4% (34) 39.5% (34)
CUORE project risk score,
Mean ± SD 5.36 ± 5.41 8.87 ± 6.99 𝑃 < 0.001
35–44 years 2.44 ± 1.71 1.5 ± 0.76 𝑃 = 0.023
45–54 years 4.75 ± 3.71 3.83 ± 2.97 𝑃 = 0.319
55–69 years 11.27 ± 6.89 11.72 ± 6.78 𝑃 = 0.771
Table 4: Comparison of psoriasis severity and cardiovascular risk.
PASI < 10 (𝑛 = 70) PASI ≥ 10 (𝑛 = 140) 𝑃 value
Age (years), mean ± SD 52.5 ± 10.3 52.1 ± 9.69 𝑃 = 0.783
Gender
Male, % (𝑛) 71.43% (50) 65.71% (92)
𝑃 = 0.404
Female, % (𝑛) 28.57% (20) 34.29% (48)
CUORE project risk score,
Mean ± SD 6.91 ± 6.75 6.74 ± 6.14 𝑃 = 0.885
single risk factor. Ten-year cardiovascular risk assessment can
be the first step to implement preventive actions in primary
care.
Several studies [12, 19–22] and our findings demonstrate
that cardiovascular diseases and their associated risk factors
are more common in patients with psoriasis than in the
general population. The cause of this elevated risk is unclear.
Some authors suggest that the profound psychological impact
of psoriasis may drive risky behaviours such as obesity and
smoking and thereby directly increase cardiovascular risk
[23]. Others have suggested that there may be some intrinsic
associated risk: elevated lipids have been documented in
psoriasis patients at the time of their initial diagnosis when
compared to nonpsoriasis controls that were matched for
body mass index (BMI) status, as well as other demographic,
clinical, and lifestyle characteristics. However, the explana-
tion of the association between psoriasis and cardiovascular
disease is likely to be more complex and multifactorial [10].
New evidence has led to the hypothesis that psoriasis confers
increased cardiovascular risk above and beyond traditional
risk factors. Psoriasis and atherosclerosis are chronic inflam-
matory diseases with a considerable overlap of inflammatory
mechanisms [24]. Involvement of T lymphocytes in psoriasis
immunopathogenesis, linked to Th1 and Th17 patterns of
immunological response, is believed to lead to a proinflam-
matory state, which has been associated with an increased
risk of cardiovascular disease [20, 25].
Recognizing the increased prevalence of cardiovascular
disease, the National Psoriasis Foundation has issued a
consensus statement that alerts providers that patients with
psoriasis may represent an emerging high-cardiovascular
risk population and thus patients with psoriasis should
be screened for cardiovascular risk factors. This consensus
statement further recommends that appropriate lifestyle and
pharmacologic therapies should be prescribed for patients
with psoriasis who are at increased risk for cardiovascular
diseases [5]. Of note, it has recently been suggested that
patients with psoriasis are inadequately screened and treated
for coronary risk factors. Underdiagnosis and undertreat-
ment of coronary risk factors may contribute to the increased
risk of cardiovascular disease in psoriasis patients [24].
5. Conclusion
It is wellestablished that psoriasis is associated with increased
risk of cardiovascular disease and increased prevalence of
cardiovascular risk factors. Screening practices and treatment
aimed at cardiovascular risk factors and disease remain a
challenge in clinical practice. It is necessary to enhance
dermatologists’, cardiologists’, internists’ and general practi-
tioners’ awareness on subclinical atherosclerosis in psoriasis
patients, so that general preventive measures and early
therapeutic interventions can be implemented reducing the
burden of high mortality events such as acute myocardium
infarction and stroke.
Treatment guidelines on management of cardiovascular
risk factors and further studies are needed to evaluate the
clinical utility of psoriasis in cardiovascular risk prediction
and investigate the impact of psoriasis treatment on cardio-
vascular outcomes.
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